Polyvalent Antibody MSC Modification for Tissue Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The low targeting efficiency of mesenchymal stem cells (MSCs) when infused intravascularly due to poor adhesion to damaged tissues, limiting their therapeutic effectiveness in regenerative medicine, is a significant challenge. Current surface modification methods using single biomolecule-functionalized cells rely on monovalent interactions, which are not sufficient for effective cell adhesion.
Innovation Solution
The development of a polyvalent antibody monomer and kit that utilize DNA monomers and antibodies, specifically anti-VCAM-1 antibodies, to enhance cell adhesion by forming polyvalent antibodies through hybridization chain reactions, which are then attached to the surface of MSCs, facilitating multivalent interactions with vascular endothelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single biomolecule-functionalized cells are used for surface modification, then the cell surface can be modified with exogenous biomolecules, but the adhesion capacity remains insufficient due to monovalent interaction
Solution Approach 1:
The patent combines multiple antibody monomers with complementary DNA sequences to form polyvalent antibodies on the cell surface. This merging of multiple binding units transforms monovalent interactions into multivalent interactions, significantly enhancing adhesion capacity while maintaining manageable system complexity through modular assembly
Solution Approach 2:
The invention creates a composite structure consisting of DNA monomers, antibodies, and cell surface components. This composite material approach allows the integration of different functional elements (DNA for specificity, antibody for binding, cell for therapeutic function) to achieve enhanced adhesion through multivalent interactions
2Ease of operation
If intravascular infusion is used for MSC delivery, then minimal invasiveness and repeat administration are achieved, but targeting efficiency drops below 1%
Solution Approach 1:
The patent introduces localized recognition capabilities to the MSC surface by engineering specific polyvalent antibody configurations that target particular vascular endothelial markers. This local quality enhancement at the cell surface level enables the cells to selectively adhere to damaged tissue sites during intravascular circulation, transforming a systemic delivery approach into a targeted therapy
Solution Approach 2:
The invention changes the binding parameters of the cell surface by introducing polyvalent antibodies with multiple binding sites. This parameter change from monovalent to multivalent interactions significantly enhances the kinetic stability and affinity of cell-endothelium binding, enabling effective targeting during intravascular infusion
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modification significantly enhances the adhesion of MSCs to damaged tissues, improving their therapeutic effectiveness by increasing the targeting efficiency and tissue repair capabilities without affecting cell proliferation or cytokine secretion.
Implementation Method 1
The development of a polyvalent antibody monomer and kit that utilize DNA monomers and antibodies, specifically anti-VCAM-1 antibodies, to enhance cell adhesion by forming polyvalent antibodies through hybridization chain reactions
Data Source
AI summary
An antibody monomer, including an antibody, and a first DNA monomer or a second DNA monomer, where the antibody is an anti-vascular cell adhesion molecule 1 (antiVCAM1) antibody. Nucleotide sequences of the first and second DNA monomers respectively consist of SEQ ID NO:1 and SEQ ID NO:2. A kit including the antibody monomer and an initiator including a nucleotide sequence consisting of SEQ ID NO: 3 is provided. This application also provides a polyvalent antibody including a first antibody monomer and a second antibody monomer, where the first antibody monomer includes the first DNA monomer and the antiVCAM1 antibody, and the second antibody monomer includes the second DNA monomer and the antiVCAM1 antibody. This application further provides a mesenchymal stem cell modified with the antibody monomer or the polyvalent antibody, and an application thereof in the treatment of tissue damage.